A multicenter real-world study demonstrates sustained low disease activity in patients with FIP1L1::PDGFRA-negative hypereosinophilic syndrome treated with mepolizumab. This research highlights the potential long-term benefits of mepolizumab in managing this rare condition.
sustained low disease activity during long term mepolizumab treatment in fip1l1 pdgfra negative hypereosinophilic syndrome a multicenter real world study
Original title: “Sustained low disease activity during long-term mepolizumab treatment in FIP1L1::PDGFRA-negative hypereosinophilic syndrome: a multicenter real-world study.”